公开(公告)号：US20180037645A1

公开(公告)日：2018-02-08

申请号：US15694374

申请日：2017-09-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brenda L. Stevens ,  Alison Witte ,  Mark W. Rixon ,  Josephine M. Cardarelli ,  Thomas D. Kempe ,  Scott R. Presnell ,  Mohan Srinivasan ,  Susan C. Wong ,  Guodong Chen ,  Hui Wei ,  Stanley R. Krystek ,  Lumelle A. Schneeweis ,  Paul O. Sheppard ,  Indrani Chakraborty

IPC: C07K16/24 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

公开(公告)号：US09644032B2

公开(公告)日：2017-05-09

申请号：US15166114

申请日：2016-05-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Zhehong Cai ,  Indrani Chakraborty ,  Marie-Michelle Navarro Garcia ,  Thomas D. Kempe ,  Alan J. Korman ,  Alexander T. Kozhich ,  Hadia Lemar ,  Mark Maurer ,  Christina Maria Milburn ,  Michael Quigley ,  Xiang Shao ,  Mohan Srinivasan ,  Kent Thudium ,  Susan Chien-Szu Wong ,  Jochem Gokemeijer ,  Xi-Tao Wang ,  Han Chang ,  Patrick Guirnalda

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3038 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/574

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

公开(公告)号：US20150086552A1

公开(公告)日：2015-03-26

申请号：US14402322

申请日：2013-05-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brenda L. Stevens ,  Alison Witte ,  Mark W. Rixon ,  Josephine M. Cardarelli ,  Thomas D. Kempe ,  Scott R. Presnell ,  Mohan Srinivasan ,  Susan C. Wong ,  Guodong Chen ,  Hui Wei ,  Stanley R. Krystek ,  Lumelle A. Schneeweis ,  Paul O. Sheppard ,  Indrani Chakraborty ,  Milan Gao ,  Steven Sheriff ,  Noah Ditto ,  Nels B. Hamacher

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。